United States Opioid Withdrawal Syndrome Market 2031 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

Opioid Withdrawal Syndrome market growing at a CAGR of 5% during the forecast period 2024-2031.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/opioid-withdrawal-syndrome-market?sb

Key Development:

United States: Recent Opioid Withdrawal Syndrome & Related Developments

✅ In December 2025, SCIENTURE detailed the upcoming commercial launch of REZENOPY® (10 mg naloxone nasal spray) the highest‐strength FDA‐approved naloxone product with wholesale readiness expected Q1 2026 and commercial availability by early Q2 2026, strengthening emergency opioid overdose response tools in the U.S. as naloxone access expands.

✅ In September 2025, the U.S. FDA finalized new policy guidance to encourage innovation in buprenorphine treatments, including sustained‐release and implantable formulations, aimed at expanding medication options that can reduce opioid withdrawal symptoms and misuse compared with traditional delivery methods.

✅ In September 2025, U.S. regulatory bodies issued draft guidance to accelerate non‐opioid analgesics development, part of broader efforts to reduce opioid reliance and limit withdrawal risk by offering safer pain management alternatives, influencing how future OUD and withdrawal therapies may emerge.

✅ In August 2025, Purdue Pharma expanded access to low‐cost opioid use disorder treatments in correctional facilities, broadening reach of standard therapies that help manage OUD and mitigate withdrawal severity among incarcerated populations.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=opioid-withdrawal-syndrome-market

Japan: Recent Opioid Withdrawal Syndrome & Related Developments

✅ In November 2025, Japan's opioid withdrawal treatment services and products segment gaining momentum, with increased research and development trends contributing to broader treatment option availability for withdrawal and OUD management pathways.

✅ In September 2025, Japanese researchers at Kyoto University published results on a novel non‐opioid analgesic called ADRIANA, which may reduce reliance on traditional opioids and consequently the incidence and severity of opioid withdrawal, with major U.S. Phase II trials underway.

✅ In recent months (2025), Japan's clinical and regulatory focus has emphasized appropriate prescription and management of opioid analgesics, underlining stricter guideline application and patient‐centered opioid reduction strategies to prevent dependence and withdrawal complications.

✅ In late 2025, Japan's addiction and substance use disorder frameworks have been increasingly discussed in national and international forums, reflecting growing recognition of opioid misuse and withdrawal care needs within healthcare systems.

Key Players:

=> USWM, LLC, Teva Pharmaceuticals USA, Inc., Braeburn Inc, Rosemont Pharmaceuticals Ltd, Mallinckrodt, Pfizer Inc, Alkermes, Inc, Vista Pharm LLC, Steris Healthcare Pvt Ltd, Accord Healthcare Inc among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/opioid-withdrawal-syndrome-market?sb

Key Segments:

By Drug Type

Lucemyra - ~25% share

Primarily used for managing opioid withdrawal symptoms; high adoption in clinical and hospital settings.

Methadone - ~30% share

Widely used in opioid replacement therapy; established presence in both hospital and outpatient treatment programs.

Buprenorphine - ~25% share

Increasingly preferred due to safer profile and ease of administration; supported by regulatory guidelines in multiple regions.

Naltrexone - ~15% share

Used for relapse prevention in opioid dependency; adoption growing in outpatient and homecare settings.

Others - ~5% share

Includes emerging therapies and adjunct medications for opioid use disorder management.

By Route of Administration

Oral - ~70% share

Dominant route due to convenience, patient compliance, and suitability for long-term treatment.

Intravenous - ~30% share

Used in hospital-based detoxification programs and acute withdrawal management; less common for outpatient use.

By Distribution Channel

Hospital Pharmacies - ~40% share

Primary distribution for inpatient treatment and supervised detox programs.

Retail Pharmacies - ~35% share

Supports outpatient opioid replacement therapy and community-based treatment programs.

Online Pharmacies - ~25% share

Growing segment due to telemedicine expansion and prescription delivery services, especially in North America and Europe.

By Region

North America - ~45% share

Largest market; high prevalence of opioid use disorder, advanced healthcare infrastructure, and regulatory support for medication-assisted treatment (MAT).

Europe - ~25% share

Strong market growth supported by national addiction treatment programs and increasing awareness.

Asia Pacific - ~15% share

Emerging market; growing awareness and healthcare investments driving adoption of MAT drugs.

South America - ~10% share

Moderate growth due to rising prevalence of opioid use and expansion of hospital and retail pharmacy networks.

Middle East & Africa - ~5% share

Nascent market with potential for growth as healthcare infrastructure and opioid addiction management programs develop.

FAQ

Q3: What is the growth rate of the Opioid Withdrawal Syndrome Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 5% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.